Candel Therapeutics, Inc. (NASDAQ:CADL – Free Report) – Stock analysts at HC Wainwright decreased their Q3 2026 earnings per share (EPS) estimates for shares of Candel Therapeutics in a note issued to investors on Thursday, August 13th. HC Wainwright analyst A. Maldonado now forecasts that the company will post earnings per share of ($0.35) for the quarter, down from their prior forecast of ($0.25). HC Wainwright has a “Buy” rating and a $23.00 price objective on the stock. The consensus estimate for Candel Therapeutics’ current full-year earnings is ($1.03) per share. HC Wainwright also issued estimates for Candel Therapeutics’ Q4 2026 earnings at ($0.30) EPS, FY2026 earnings at ($1.33) EPS, FY2027 earnings at ($0.19) EPS and FY2030 earnings at $2.07 EPS.
CADL has been the subject of a number of other research reports. Stifel Nicolaus initiated coverage on shares of Candel Therapeutics in a report on Monday, July 13th. They issued a “buy” rating and a $22.00 price objective for the company. Bank of America increased their target price on shares of Candel Therapeutics from $9.00 to $12.00 and gave the stock a “neutral” rating in a report on Friday. UBS Group restated a “buy” rating on shares of Candel Therapeutics in a research report on Monday. Wall Street Zen lowered shares of Candel Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Candel Therapeutics in a research note on Friday, July 17th. Eight research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Candel Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $19.29.
Candel Therapeutics Stock Performance
CADL stock opened at $12.16 on Monday. The company has a current ratio of 16.09, a quick ratio of 16.09 and a debt-to-equity ratio of 0.38. The firm has a market cap of $930.48 million, a P/E ratio of -8.62 and a beta of -0.51. Candel Therapeutics has a 12-month low of $4.35 and a 12-month high of $12.49. The stock’s 50 day simple moving average is $9.75 and its 200 day simple moving average is $7.45.
Candel Therapeutics (NASDAQ:CADL – Get Free Report) last issued its earnings results on Thursday, August 13th. The company reported ($0.52) EPS for the quarter, missing the consensus estimate of ($0.24) by ($0.28).
Insiders Place Their Bets
In related news, CTO Seshu Tyagarajan sold 7,000 shares of the company’s stock in a transaction on Monday, June 29th. The stock was sold at an average price of $10.02, for a total transaction of $70,140.00. Following the completion of the transaction, the chief technology officer directly owned 83,865 shares in the company, valued at $840,327.30. This represents a 7.70% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Francesca Barone sold 23,447 shares of the stock in a transaction on Monday, June 29th. The stock was sold at an average price of $10.06, for a total value of $235,876.82. Following the completion of the sale, the insider directly owned 77,362 shares in the company, valued at $778,261.72. This represents a 23.26% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 14.30% of the stock is owned by corporate insiders.
Hedge Funds Weigh In On Candel Therapeutics
Several institutional investors have recently modified their holdings of the company. BlackRock Inc. acquired a new stake in shares of Candel Therapeutics in the 2nd quarter worth about $51,181,000. Vanguard Group Inc. boosted its stake in Candel Therapeutics by 12.3% during the 3rd quarter. Vanguard Group Inc. now owns 2,007,112 shares of the company’s stock valued at $10,236,000 after purchasing an additional 219,563 shares during the period. Geode Capital Management LLC boosted its stake in Candel Therapeutics by 5.3% during the 4th quarter. Geode Capital Management LLC now owns 977,512 shares of the company’s stock valued at $5,524,000 after purchasing an additional 49,315 shares during the period. Halter Ferguson Financial Inc. grew its position in Candel Therapeutics by 20.9% in the 1st quarter. Halter Ferguson Financial Inc. now owns 904,051 shares of the company’s stock worth $4,430,000 after purchasing an additional 155,996 shares during the last quarter. Finally, State Street Corp grew its position in Candel Therapeutics by 15.0% in the 4th quarter. State Street Corp now owns 792,218 shares of the company’s stock worth $4,476,000 after purchasing an additional 103,452 shares during the last quarter. Institutional investors own 13.93% of the company’s stock.
Key Stories Impacting Candel Therapeutics
Here are the key news stories impacting Candel Therapeutics this week:
- Positive Sentiment: HC Wainwright raised its price target for Candel Therapeutics to $12.00, providing a more favorable valuation signal. However, the new target is roughly in line with the stock’s recent trading level, suggesting limited implied upside from that estimate. Candel Therapeutics Price Target Raised to $12.00
- Neutral Sentiment: An analyst forecast for Candel’s fiscal 2028 earnings was reported, giving investors a longer-term reference point, although the article does not indicate a material change to the company’s near-term valuation. What is HC Wainwright’s Forecast for CADL FY2028 Earnings?
- Negative Sentiment: HC Wainwright adopted a pessimistic outlook for Candel’s third-quarter earnings, adding pressure to expectations for the company’s next results. HC Wainwright Has Pessimistic Outlook of CADL Q3 Earnings
- Negative Sentiment: An analyst reduced Candel’s third-quarter EPS estimate, signaling expectations for a wider loss or weaker-than-previously-forecast results. Q3 EPS Estimate for Candel Therapeutics Decreased by Analyst
- Negative Sentiment: Candel shares previously fell after disappointing quarterly earnings. The company reported a quarterly loss of $0.52 per share, worse than the $0.24 analyst consensus, highlighting continued earnings risk. Candel Therapeutics Stock Price Down 4.6% on Disappointing Earnings
- Negative Sentiment: Wall Street Zen downgraded Candel Therapeutics to Sell, reinforcing the cautious view surrounding the company’s profitability and earnings outlook. Wall Street Zen Downgrades Candel Therapeutics to Sell
About Candel Therapeutics
Candel Therapeutics (NASDAQ:CADL) is a clinical-stage immuno-oncology company focused on the development of next-generation oncolytic viral therapies designed to treat solid tumors. The company’s lead candidate, CAN-2409, is a locally administered, gene-delivered viral therapy engineered to selectively replicate in cancer cells and induce immunogenic cell death. Candel leverages proprietary virus engineering platforms to enhance tumor-specific replication and stimulate anti-tumor immune responses, aiming to improve outcomes for patients with high unmet medical needs.
In addition to its lead program, Candel’s pipeline includes CAN-3110, an oncolytic herpes simplex virus targeting recurrent high-grade glioma, and other novel viral constructs being explored for a variety of solid tumor indications.
Further Reading
- Five stocks we like better than Candel Therapeutics
- Commodities Are Booming, But These 3 ETFs Tell Different Stories
- 3 Active ETFs Making Big Moves in August
- This ETF Is Outperforming by Avoiding the S&P 500’s Biggest Problem
- Birkenstock Beats the Skeptics—But Not on EPS
Receive News & Ratings for Candel Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Candel Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
